Company intelligence / Profile preview

NeuTherX

California, United States

Ownership: Private
Development stage: Other

Overview

NeuTherX uses patient-derived brain organoids with AI-driven analytics to enable precise and accelerated drug discovery, with its technology aimed at lowering failure rates in neuropsychiatric disorder therapeutics. No specific clinical results are disclosed[1].

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Drug Discovery Services

Partnerships

Verseon

Beyond the preview

Go deeper on NeuTherX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuTherX.

Explore the full profile